anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cardiac function is under neural regulation; however, brain regions in the cerebral cortex responsible for regulating cardiac function remain elusive. In this study, retrograde trans-synaptic viral tracing is used from the heart to identify a specific population of the excitatory neurons in the primary motor cortex (M1) that influences cardiac function in mice. Optogenetic activation of M1 glutamatergic neurons increases heart rate, ejection fraction, and blood pressure. By contrast, inhibition of M1 glutamatergic neurons decreased cardiac function and blood pressure as well as tyrosine hydroxylase (TH) expression in the heart. Using viral tracing and optogenetics, the median raphe nucleus (MnR) is identified as one of the key relay brain regions in the circuit from M1 that affect cardiac function. Then, a mouse model of cardiac injury is established caused by myocardial infarction (MI), in which optogenetic activation of M1 glutamatergic neurons impaired cardiac function in MI mice. Moreover, ablation of M1 neurons decreased the levels of norepinephrine and cardiac TH expression, and enhanced cardiac function in MI mice. These findings establish that the M1 neurons involved in the regulation of cardiac function and blood pressure. They also help the understanding of the neural mechanisms underlying cardiovascular regulation.
Background and Objective: Lung transplantation is the only life-extending therapy for end-stage pulmonary disease patients, but its risks necessitate an understanding of outcome predictors, with the frailty index and nutritional status being key assessment tools. This study aims to evaluate the relationship between preoperative frailty and nutritional indexes and the postoperative mortality rate in patients receiving lung transplants, and to determine which measure is a more potent predictor of outcomes. Materials and Methods: This study reviewed 185 adults who received lung transplants at a single medical center between January 2013 and May 2023. We primarily focused on postoperative 7-year overall survival. Other outcomes measured were short-term mortalities, acute rejection, kidney complications, infections, and re-transplantation. We compared the predictive abilities of preoperative nutritional and frailty indicators for survival using receiver operating characteristic curve analysis and identified factors affecting survival through regression analyses. Results: There were no significant differences in preoperative nutritional indicators between survivors and non-survivors. However, preoperative frailty indicators did differ significantly between these groups. Multivariate analysis revealed that the American Society of Anesthesiologists Class V, clinical frailty scale, and Charlson Comorbidity Index (CCI) were key predictors of 7-year overall survival. Of these, the CCI had the strongest predictive ability with an area under the curve of 0.755, followed by the modified frailty index at 0.731. Conclusions: Our study indicates that for critically ill patients undergoing lung transplantation, frailty indexes derived from preoperative patient history and functional autonomy are more effective in forecasting postoperative outcomes, including survival, than indexes related to preoperative nutritional status.
Mismatch repair deficient CRC or EC patients treated with 200mg i.v. pembrolizumab q3w and Ataluren at MTD.
Group 1 will be assigned to the Virtual Realtity Headset. Participants will wear the headset for at least 10 minutes prior to the planned procedure. Subjects will receive standard procedure. The VR Headset will be removed 10 minutes after the planned procedure.
Intrauterine adhesion, also known as Asherman's syndrome, is the partial or complete occlusion of the uterine cavity as a result of endometrium damage. Most intrauterine adhesions patients manifest amenorrhea, reduced menstrual pattern, infertility, and intrauterine growth restriction, which seriously affect their reproductive health. Currently, hysteroscopy is the preferred method of intrauterine adhesions diagnosis and treatment. However, because intrauterine adhesions patients generally have poor endometrium repair capability, the incidence rate of reformation of intrauterine adhesions ranging from 20%-62.5% in those with severe adhesions. The successful pregnancy rate after treatment in severe Asherman's syndrome is reported to be consistently lower, only 33%. The prevention of intrauterine adhesions recurrence after trans-cervical resection of adhesion is clinically important but difficult. Therefore, this study was conducted.
This was a multicenter, randomized, double-blind, parallel group, active-controlled, study to evaluate the efficacy and safety of sacubitril/valsartan compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. Specifically, the study evaluated the effect of sacubitril/valsartan compared to the active comparator valsartan in the reduction of the rate of CV death and total HF hospitalizations in patients with HFpEF. The trial consisted of two periods: (1) a single-blind treatment run-in epoch that lasted from 3 to 8 weeks, in which patients received valsartan 80 mg bid, followed by sacubitril/valsartan 100 mg bid and (2) a double-blind randomized treatment epoch (sacubitril/valsartan 200 mg bid or valsartan 160 mg bid). In this study, investigators were responsible for assessing and submitting all events which could potentially fulfill the criteria for the primary, secondary, or other clinical endpoints to a Clinical Endpoint Committee (CEC). Investigator reported events were assessed by the CEC for adjudication.

For angioedema or angioedema-like events, investigators completed an Adjudication Questionnaire for an Angioedema-like Event form. All angioedema reports were forwarded to an Angioedema Adjudication Committee (AAC) by Novartis for assessment.
In 2003, Surgeon General Richard Carmona stated that low health literacy was "one of the largest contributors to our nation's epidemic of overweight and obesity." This assertion is supported by recent studies which have found that low health literacy or numeracy is associated with poorer caregiver breastfeeding knowledge, incorrect mixing of infant formula, difficulty understanding food labels and portion sizes, and higher Body Mass Index (BMI) in adults and children. Of particular concern is the impact of the obesity epidemic on our youngest children. Over 26% of preschool children are now overweight (BMI≥85%) or obese (BMI≥95%) (based on 2007 Health and Human Services/Centers for Disease Control Expert Panel definitions). Rates of obesity in preschool children have doubled over the past decade, with the highest increases among low income and minority children-- the same communities most affected by low health literacy.

To date, clinical efforts to prevent or treat childhood obesity have had limited efficacy. Efforts need to start early, because children who are overweight by age two are five times as likely to become overweight adolescents, and subsequently at higher risk for obesity-related complications including early-onset Type-2 Diabetes and cardiovascular disease. No published clinical studies have rigorously addressed obesity prevention prior to age 2 with a specific low-literacy and numeracy focus. Addressing caregiver health literacy in early childhood is an innovative strategy to promote healthy nutrition and activity among these families and prevent unhealthy weight gain across the child's life, which would have great public health significance by preventing both child and adult chronic illness.

The proposed study is a multi-site randomized, controlled trial to assess the efficacy of a low-literacy/numeracy-oriented intervention designed to promote healthy family lifestyles and to prevent early childhood obesity. The intervention will be delivered through pediatric resident physicians in primary care settings in under-resourced communities. Four academic medical centers will be randomized: Vanderbilt University, the University of Miami, the University of North Carolina at Chapel Hill, and New York University. Two centers will receive the intervention, while the other two centers will receive an active control. At each site, a cohort of 250 English- or Spanish-speaking caregiver-child dyads will be enrolled and followed from the child's 2 month well-child visit through the 24-month well-child visit. The intervention will include a low-literacy-oriented toolkit for pediatric residents to use with families and clear health communication training for the pediatric residents. At control sites, pediatric residents will provide "usual care" with respect to lifestyle counseling, but they will also receive an injury-prevention education program to act as an attention control. The primary hypotheses are that the intervention will improve family dietary and physical activity behaviors and that it will reduce the rate of childhood overweight (BMI≥85%) at age 24 months.
Broadly, this study aims to answer three questions. (1) Is it feasible to call discharged trauma patients on their mobile phones to check up on them? (2) Can a defined set of questions help determine which discharged trauma patients require further medical care (and which discharged trauma patients do not require further medical care)? (3) Will checking in on discharged trauma patients reduce their experience of disability and economic consequences?

If an individual was a trauma patient who was admitted at and then discharged from one of the study's partner hospitals in Cameroon, the discharged individual (hereafter referred to as "the participant') will be receiving phone calls from one of the study's research assistants at the following post-discharge timepoints: 2 weeks, 1 month, 3 months, and 6 months. Whether the research assistant administers the defined set of questions developed by the study's investigators (see question 2, above) will depend on when the participant was discharged from the hospital. Regardless, all participants will be asked other important questions about the injury and any associated disabilities and economic consequences.
The present invention relates to a protein medicine microcapsule which is suitable for preparing aerosol. A protein medicine is wrapped on a microcapsule, and the particle diameter of each of most of the microcapsules is less than 10 micrometers; the present invention has the action of slow release and controlled release and can maintain the bioactivity of the medicine. The present invention also relates to a compound which comprises a microcapsule and a carrier, the microcapsule comprises the protein medicine of the present invention, and the carrier can be accepted by pharmacy. The present invention also relates to imbedibility aerosol of the protein medicine, which comprises a microcapsule and a propellant, wherein the microcapsule comprises the protein medicine of the present invention; the imbedibility aerosol can be prepared into the preparation of an aerosol by which administration can be absorbed. Administration can be realized in the mode of inhalation, the protein medicine is transported to a respiratory system so the purpose of therapy is achieved. The present invention provides an ideal novel dosage form used for conveying the protein medicine.
The investigators will conduct a randomized controlled human exposure crossover study among about 30 healthy young adults in Shanghai, China. Each subject will be exposed twice: once to the high temperature (32℃) and once to moderate temperature (22℃) in a chamber for about 2 hours. During the exposure session, each subject will be requested to rest. Health examinations will be conducted immediately prior to exposure, during the period of exposure and after exposure. Health examinations include symptom questionnaire, blood pressure tests, cognitive function tests, magnetic resonance imaging, skin tests, spirometry, and Holter monitoring. Investigators plan to collect blood, urine and oropharyngeal swabs samples.
The invention discloses straw compound enzyme liquid and application thereof to skin care and cosmetics. The straw compound enzyme liquid is a multi-enzyme system, wherein straw is used as the raw material and subjected to fermentation, ultrasonic hydrolysis, centrifugal separation and the like to prepare the straw compound enzyme liquid. The straw compound enzyme liquid has the advantages of high catalytic activity, high catalytic efficiency and a good catalytic effect. The straw compound enzyme liquid can also be further refined into a refined compound enzyme. The straw compound enzyme liquid or the refined compound enzyme can be directly used for daily cleaning of the skin or care of the skin suffering from edema, scalds, chapping, prickly heat, eczema and other symptoms or can be added into daily skin cleaning supplies, skin care agents and cosmetics. The side product grass pureed produced in the preparation process can be used as a mask material, and grass residues can be mixed with organic fertilizer and used for preparing a plant seedling growing matrix. The pH of the straw compound enzyme liquid is between 7 and 7.5, the weight is between 0.95 and 0.98, the straw compound enzyme liquid is brown in color with the smell of rosin and sandalwood, the preparation method is simple, the preparation process is environmentally friendly without pollution, and cost is low.
The invention discloses a hybridoma cell strain, an anti-conotoxin alpha-GI monoclonal antibody and application thereof, wherein the preservation number of the hybridoma cell strain is CCTCC NO: C202340. The anti-conotoxin alpha-GI monoclonal antibody is secreted by the hybridoma cell strain and can specifically bind with the conotoxin alpha-GI. Based on the cloned Anti-conotoxin alpha-GI monoclonal antibody-444-No. 9 light and heavy chain variable region gene, the molecular subtype of the antibody is identified as mouse IgG1Kappa, and the corresponding germ line genes are respectively from Musmus IGHV1-9 x 01F and Musmus IGKV4-53 x 01F. In vitro functional research shows that the recombinant anti-conotoxin alpha-GI monoclonal antibody can specifically bind to the conotoxin alpha-GI, and ELISA experiments show that the binding activity is definite. In vivo studies in mice show that antibodies with different concentrations of Anti-GI-444-No.9 can respectively and remarkably improve animal mortality caused by LD50 dose alpha-GI contamination, and can be used for first aid and treatment of poisoning of alpha-GI toxin.
Systems, methods, and devices for interactive workplace health therapy are disclosed, which include a movement station having a processor, memory, a user interface communicatively coupled to the processor, a communication interface, and at least one sensor. At least one piece of health therapy equipment is provided in a receptacle of the movement station. The sensor of the movement station is arranged to detect a mobile computing device that is in proximity of the movement station, and a user associated with the mobile computing device is identified. Based on the identity of the user, user profile information is retrieved from a user profile database. At least one directive is presented to the identified user via the user interface. The directive instructs the user in the use of the at least one piece of health therapy equipment. Information regarding the user's use of the at least one piece of health therapy equipment is collected and stored in the user profile database.
The invention relates to a novel process for the isolation of a hepatoprotective agent Silymarin from the seeds of the plant  Silybum marianum  comprising (i) Precooling the seeds to (−) 20° C. for 24 hours in a deep freezer/cold room. (ii) Powdering the cooled seeds in a hammer mill, fitted with about 40 mesh discharge screen. (iii) Defatting the seeds by extracting with hexane in a soxhlet type extractor to remove the total quantity of fatty oil without using a scrain. (iv) Extracting the defatted seeds with acetonitrile at 20-30° C. to extract silymarin fraction. (v) Concentration of the sensitive silymarin fraction under vacuum in a agitated wiped thin film evaporator (vi) stirring the silymarin such dry powder with cold dichloromethane at 5° C. followed by filtration and drying with a slow purge of nitrogen gas. (vii) Further purification of silymarin by suspending in 5 times its weight of acetonitrile and precipitating by 8-12 times its weight of water at 20° C. (viii) Filtering the precipitated silymarin in a closed vacuum filter and having 1-2 μm screen washing the cake three times with distilled water (ix) Drying of Silymarin cake in vacuum oven to obtain substantially pure silymarin.
The invention discloses an external medicament for treating herpes zoster. The external medicament is characterized by consisting of the following medicaments by weight: 25-60g of hedgehog skin, 45-70g of humifuse euphorbia herb and 40-60g of sesame oil. A preparation method of the external medicament comprises the following steps of: putting hedgehog skin bought from a drug store onto a tile for drying and smashing, and sieving with a 100-mesh sieve; and drying humifuse euphorbia herb, smashing, sieving with a 100-mesh sieve, mixing and stirring the smashed hedgehog skin powder, humifuse euphorbia herb powder and sesame oil uniformly, sealing and storing for seven days. The external medicament has the beneficial effects that: the functions of clearing away heat and toxic materials, removing dampness through diuresis, cooling blood and relieving pain are achieved by combining three Chinese medicinal components, i.e., hedgehog skin, humifuse euphorbia herb and sesame oil in a Chinese medicine for treating herpes zoster and the preparation method thereof. The external medicament has the effects of clearing away heat and toxic materials, relieving fever, removing stagnancy, cooling blood, removing dampness through diuresis, promoting qi circulation, relieving pain and treating swelling and malignant sore. Compared with the conventional medicament for treating herpes zoster, the external medicament has the advantages of freeness from side effects due to the adoption of a pure Chinese medicinal preparation, easiness in administration, good curative effect and short treatment course.
Non-alcoholic steatohepatitis (NASH) may be associated with tissue fibrotic changes and can be treated via different therapeutic tools which may however either initiate weak or long-term side effects that minimize its use. Empagliflozin (EMPA) is an oral anti-diabetic drug which has characteristic effects during hepatic steatosis regarding lipid accumulation and insulin resistance. In this study, we aimed to investigate an additional mechanism through which EMPA can exert and potentiate its anti-inflammatory and anti-fibrotic effects in NASH rat model. Male Wistar albino rats fed on high fat diet (HFD) and 20% fructose in drinking water for 18 weeks and received EMPA (30 mg/kg/day, orally) starting from week 11. Body and liver weights, homeostatic model assessment of insulin resistance (HOMA-IR), lipid profile, liver function tests, other biochemical and histological parameters were determined. HFD joined with fructose intake significantly increased body and liver weights, HOMA-IR value, hepatic inflammatory and fibrotic markers, liver transaminases, hepatic expression of nuclear factor-kappa B (NF-κB), sex determining region Y box 9 (SOX 9), and osteopontin (OPN) with significant decrease in hepatic osteocalcin (OCN). Intense hepatic lesions with severe microsteatosis and deposition of collagen fibers were clearly observed. Effectively, EMPA restored the normal liver functions, downregulated hepatic inflammatory cytokines, NF-κB, SOX 9, OPN, and increased OCN level. These results highlight another pathway illustrated the anti-fibrotic effects of EMPA against liver fibrosis probably through downregulation of NF-κB/SOX 9/OPN signaling along with upregulation of hepatic OCN which may potentiate the valuable anti-inflammatory and anti-fibrotic effects of EMPA.
OBJECTIVE: Atrial fibrillation (AF), if left untreated, is associated with increased intermediate and long-term morbidity/mortality. Surgical treatment for AF is lacking standardization in patient selection and lesion set, despite clear support from multi-society guidelines. The aim of this study was to analyze a statewide cardiac surgery registry to establish whether or not there is an association between center volume and type of index procedure with performance of surgical ablation (SA) for AF, the lesion set chosen, and ablation technology used.
METHODS: Adult, first-time, nonemergency patients with preoperative AF between 2014 and 2022 excluding standalone SA procedures from a statewide registry of Society of Thoracic Surgeons data were included (N = 4320). AF treatment variability by hospital volume (ordered from smallest to largest) and surgery type were examined with χ2 analyses. Hospital-level Spearman correlations compared hospital volume with proportion of AF patients treated with SA.
RESULTS: Overall, 37% of patients with AF were ablated at the time of surgery (63% of mitral procedures, 26% of non-mitrals) and 15% had left atrial appendage management only. There was a significant temporal trend of increasing performance of SA for AF over time (Cochran-Armitage = 27.8; P < .001). Hospital cardiac surgery volume did not correlate with the proportion of AF patients treated with SA (rs = 0.19; P = .603) with a rate of SA below the state average for academic centers. Of cases with SA (n = 1582), only 43% had a biatrial lesion set. Procedures that involved mitral surgery were more likely to include a biatrial lesion set (χ2 = 392.3; P < .001) for both paroxysmal and persistent AF. Similarly, ablation technology use was variable by type of concomitant operation (χ2 = 219.0; P < .001) such that radiofrequency energy was more likely to be used in non-mitral procedures.
CONCLUSIONS: These results indicate an increase in adoption of SA for AF over time. No association between greater hospital volume or academic status and performance of SA for AF was established. Similar to national data, the type of index procedure remains the most consistent factor in the decision to perform SA with a disconnect between AF pathophysiology and decision making on the type of SA performed. This analysis demonstrates a gap between evidence-based guidelines and real-world practice, highlighting an opportunity to confer the benefits of concomitant SA to more patients.
The universe of the research; between July-September 2022, patients who are intubated on a mechanical ventilator at 32-36 weeks of gestation (middle preterm group) in Gaziantep Cengiz Gökçek Obstetrics and Pediatrics Hospital Neonatal Intensive Care Unit will consist of. In order to determine the sample size of the study, power analysis was performed using the G\*Power (V3.1.9.7) program. According to Cohen's effect size coefficients; Assuming that the effect size (f = 0.4) of the evaluations to be made between four independent groups will be large/large, Taplak and Bayat (2021) found the effect size as 0.932 as a result of the Power analysis based on the PIPP-R results. In this study, it was determined that there should be at least 15 people in all groups (Fetal position, Swaddling, Prone position and control group) according to the new calculation made with 0.932 effect size, 5% alpha (two-sided) and 99% power. Considering that there may be losses during the study, each group will form a sample of 100 infants, 25 infants each. Random assignment of babies to groups will be carried out by the researcher through a computer program (https://www.randomizer.org)/. After determining the groups of premature babies randomly, one group will be given fetal position, one group swaddling position and one group prone position before, during and after endotracheal aspiration. Pain scores (PIPP-R), comfort scores (Comfort Scale) and physiological parameters (Heart peak beat, oxygen saturation value measured by pulse oximetry) 3 minutes before, during and after these nursing practices in the 1st and 3rd minutes after the procedure.